CNTB - Connect Biopharma Holdings Limited News

Oppenheimer Initiates Coverage On Connect Biopharma Hldgs with Outperform Rating, Announces Price Ta

Oppenheimer analyst Mazahir Alimohamed initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB

Piper Sandler Initiates Coverage On Connect Biopharma Hldgs with Overweight Rating, Announces Price

Piper Sandler analyst Biren Amin initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with

HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) w

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluati

– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to rep

12 Health Care Stocks Moving In Tuesday's After-Market Session

This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Ana

marketbeat.com

Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026

Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart p

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Conne

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned ba

seekingalpha.com

Connect Biopharma: New Market Opportunity In The Emergency Setting

Connect Biopharma Holdings is rated a risky Buy, with high upside potential hinging on mid-2026 Phas

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Fo

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Con

12 Health Care Stocks Moving In Wednesday's After-Market Session

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or CO

seekingalpha.com

Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Upda

Connect Biopharma Announces $20.2 Million Private Placement Financing

Funding from new and existing investors extends anticipated cash runway into the second half of 2027

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, w

Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademik

– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pu

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Recommendation of “Mo

Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) have ear

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented i

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Con

Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Co

Connect Biopharma Touts Rademikibart as Fast-Acting Option for Acute Asthma, COPD Flare-Ups at Confe

Connect Biopharma (NASDAQ: CNTB) CEO Barry Quart told investors at Oppenheimer's 36th Annual Healthc

BML Capital Management LLC Sells 554,058 Shares of Connect Biopharma Holdings Limited Sponsored ADR

BML Capital Management LLC cut its stake in Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ

Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Con

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Rating of “Moderate B

Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) have bee

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Receives Average Rating of “Moderate

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been given a c

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities f

– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potenti

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session